Gallbladder cancer accounts for a small fraction of all gastrointestinal diagnoses, leaving patients stranded between generalized protocols and scarce disease-specific literature. In 2024, our founders recognized that fragmented oncology resources delayed critical second opinions and left families bearing the administrative weight of trial discovery entirely alone.
Our 501(c)(3) charter operates on dual tracks: immediate bedside navigation checklists for newly diagnosed households, paired with targeted seed funding for translational biliary oncology research. By uniting clinical investigators, oncologists, and families into an accountable registry, we ensure rare disease advocacy receives rigorous institutional priority.
Patients first, validated science, and total fiscal openness in every grant.
We reject bureaucratic distance. Every allocated dollar, research fellowship, and peer cohort is governed by clinicians and families working to eliminate biliary cancer mortality.
Connect with leadership
We welcome inquiries regarding scientific advisory board appointments, institutional sponsorships, and clinical research collaborations across North America.